SCHEMBL20230463

SCHEMBL20230463

Cc1cc(-c2ncn(C=C(C(N)=O)c3cccnc3)n2)cc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XPO1 O14980 7/20 0.68
RANBP1 P43487 1/20 0.68
KCNH2 Q12809 1/20 0.68
ESR1 P03372 1/20 0.44
HTR1A P08908 1/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
HRH1 P35367 1/20 0.44
PDE4D Q08499 1/20 0.44
SLC29A1 Q99808 1/20 0.44
TRPA1 O75762 1/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
HSP90AA1 P07900 1/20 0.35
SYK P43405 1/20 0.35
CSF1R P07333 2/20 0.35
ELANE P08246 1/20 0.35
BRAF P15056 1/20 0.35
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17788714 1.00 XPO1 (0.68) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788715 1.00 XPO1 (0.68) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16323808 0.93 XPO1 (0.77) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16323810 0.93 XPO1 (0.77) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16361442 0.93 XPO1 (0.77) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788712 0.92 XPO1 (0.56) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788713 0.92 XPO1 (0.56) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788710 0.92 XPO1 (0.56) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL20235095 0.91 XPO1 (0.61) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL21074525 0.91 XPO1 (0.61) XPO1RANBP1KCNH2ESR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Karyopharm Therapeutics Inc. 2018-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, XPO5, XPOT XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.